34 reports

One unit refers to one Mycobacterium Diagnostic test.

  • Tuberculosis
  • Australasia
  • Demand
  • Market Size
  • Supply

Globally, nearly ## million cases of tuberculosis are reported annually resulting in approximately ## million premature deaths each year.

  • Tuberculosis
  • India
  • World
  • Epistem Holdings Plc
  • GlobalData's company

MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* CLINICAL TRIALS BY PHASE IN E## COUNTRIES MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* MYCOBACTERIUM TUBERCULOSIS INFECTION

  • Anti-Infective
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World

The prominent features of this report are - ##.

  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World

Steven Reed, IDRI founder and chief scientific officer, said, " Tuberculosis is one of the most widespread, persistent and deadly global health problems.

  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • Vaccine
  • World

GlobalData genedrive plc reported one medical equipment deal in YTD 2018.

  • Tuberculosis
  • APAC
  • United Kingdom
  • United States
  • World

Our system has the potential to drive major advances in rapid diagnosis of immunologically complex conditions such as tuberculosis. "

  • Diagnostics
  • Tuberculosis
  • United States
  • Litigation And Patent
  • MBio Diagnostics, Inc.

TUBERCULOSIS COMPLEX SPECIATION TEST.

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • Company Financials
  • QIAGEN N.V.

GlobalData Qurient Co Ltd' s, deal volume decreased from one pharmaceuticals & healthcare deal in 2016 to zero pharmaceuticals & healthcare deals in 2017.

  • Pharmaceutical
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.

One of these preclinical compounds NITD##, blocks MmpL##, a protein essential for the TB bacterium' s survival.

  • Pathology
  • Tuberculosis
  • World
  • Company
  • TB Drug Development, Inc.

This agreement enables Janssen Pharma and FIND to accelerate access to tuberculosis (TB) diagnosis, treatment and care.

  • Tuberculosis
  • Belgium
  • United States
  • Company
  • Janssen Biotech, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World

The study was conducted by researchers from Great Basin and the Public Health Research Institute Tuberculosis Center at the University of Medicine and Dentistry of New Jersey.

  • Infectious Disease
  • Tuberculosis
  • Japan
  • United States
  • GlobalData's company

Our system has the potential to drive major advances in rapid diagnosis of immunologically complex conditions such as tuberculosis. "

  • Diagnostics
  • Tuberculosis
  • United States
  • Litigation And Patent
  • MBio Diagnostics, Inc.

## Cystic Fibrosis ## Pneumonia ## Respiratory Diseases ## Tuberculosis ## Ventilator Associated Pneumonia ## Indication No of Products Avisa Pharma Inc - Pipeline Analysis Overview AVISA PHARMA INC - KEY FACTS AVISA PHARMA INC - MAJOR PRODUCT

  • Pathology
  • Tuberculosis
  • United States
  • Product Initiative
  • Avisa Pharma Inc.

The company discovers and validates novel biomarkers for tuberculosis.

  • Diagnostics
  • Tuberculosis
  • Australia
  • Product Initiative
  • Tyrian Diagnostics Limited

It' s estimated that up to one-third of the world' s population is infected with M. tuberculosis, the bacterium that causes TB.

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States
  • Company

Tuberculosis ## Viral Infections ## Human Papilloma Virus Infection ## John Cunningham Virus Infection ## Leishmaniasis ## Liver Cancer ## Lung Cancer ## Lyme Disease ## Malaria ## Melanoma ## Pancreatic Cancer

  • DNA
  • Tuberculosis
  • United States
  • Company
  • Trovagene, Inc.

Tuberculosis ## Zika Virus Infection ## Tumor ## Phenylketonuria ## Scrub Typhus Infection ## Sexually Transmitted Disease ## Chlamydia Infection ## Congenital Adrenal Hyperplasia ## Flu ## G##PD Deficiency ## Hepatitis

  • Infectious Disease
  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • GlobalData's company

Aeras Global TB Vaccine Foundation Inc(Aeras) is a nonprofit biotechnology organization that develops tuberculosis (TB) vaccines.

  • Pathology
  • Tuberculosis
  • China
  • Corporate Finance
  • GlobalData's company

The agreement enables FIND, Cepheid and Rutgers to develop next-generation test for mycobacterium tuberculosis.

  • Medical Supply
  • Tuberculosis
  • United States
  • M&A
  • Cepheid

The study was conducted by researchers from Great Basin and the Public Health Research Institute Tuberculosis Center at the University of Medicine and Dentistry of New Jersey.

  • Infectious Disease
  • Tuberculosis
  • Japan
  • United States
  • GlobalData's company

This system will help us speed up the process of finding treatments and vaccines for human tuberculosis, an infection that kills ##. ## million people per year. "

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United Kingdom
  • BioInvent

In addition, one study evaluates a new combination of existing antibiotics to treat pulmonary tuberculosis (TB), including multidrug-resistant TB.

  • Cancer
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States

IT IS DESIGNED TO DETECT THE PRESENCE OF TUBERCULOSIS BACTERIA (MYCOBACTERIUM TUBERCULOSIS) IN THE PATIENT S BLOOD SAMPLE.

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • World
  • QIAGEN N.V.

Sequella retains all rights to commercialize B-Smart technology worldwide for indications other than tuberculosis, and for territories other than the US for tuberculosis.

  • Pathology
  • Tuberculosis
  • United States
  • Deals & Alliance

BioVersys provides one of its most innovative targets focused on gram-negative pathogens into this partnership.

  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance
  • Bioversys

The timeline of development is from April 2016 through October 2017, for one year and seven months.

  • Diagnostics
  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance